Table 1.

Differentially expressed miRNAs between benign and malignant on microarray data. 14 miRNAs were up-regulated (A) and 20 were down-regulated (B). The right column represents the fold difference of each miRNAs relative to pooled samples.

Upregulated miRNA in malignant compared with benign thyroid neoplasm
miRNA	p-value	Fold change
hsa-miR-146b-5p	3.5E-03	5.00
hsa-miR-222	6.1E-03	2.77
hsa-miR-221	2.2E-01	1.84
hsa-miRPlus-E1246	2.3E-01	1.36
hsa-miRPlus-E1218	1.6E-02	1.35
hsa-miRPlus-E1093	3.1E-02	1.29
hsa-miR-32*	1.9E-02	1.26
hsa-miRPlus-E1212	1.5E-02	1.26
hsa-miRPlus-E1175	3.0E-02	1.25
hsa-miRPlus-E1030	3.2E-01	1.25
hsa-miRPlus-E1112	3.4E-02	1.21
hsa-miR-744	7.2E-01	1.21
hsa-miR-30b*	2.8E-01	1.18
hsa-miRPlus-E1043	3.8E-01	1.18
A

Downregulated miRNA in malignant compared with benign thyroid neoplasm
miRNA	p-value	Fold change
hsa-miR-451	1.1E-01	−2.91
hsa-miR-7	4.8E-02	−2.74
hsa-miR-144	1.7E-02	−2.10
hsa-miR-374a	4.2E-03	−1.98
hsa-miR-126	3.8E-05	−1.96
hsa-miR-143	1.6E-02	−1.76
hsa-miR-30e	2.1E-04	−1.62
hsa-let-7g	5.0E-03	−1.57
hsa-miR-335	3.5E-03	−1.56
hsa-miR-101	6.2E-02	−1.55
hsa-miRPlus-F1195	1.8E-05	−1.54
hsa-miR-26b	3.5E-02	−1.52
hsa-let-7f	8.6E-03	−1.50
hsa-miR-30c	3.1E-03	−1.49
hsa-miR-193a-3p	5.1E-04	−1.49
hsa-miR-30b	3.1E-03	−1.46
hsa-miR-145	4.5E-02	−1.46
hsa-miR-30a	1.4E-02	−1.45
hsa-miR-195	1.7E-05	−1.41
hsa-miR-22	5.9E-05	−1.24
B.